SCHEMBL10072361

SCHEMBL10072361

CCc1nn2c(-c3ccc(F)cc3)cc(N3CCC[C@H]3CO)nc2c1-c1ccc(C)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.47
HPGD P15428 2/20 0.47
GAA P10253 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HSD17B10 Q99714 1/20 0.47
PKM P14618 1/20 0.44
FPR2 P25090 2/20 0.43
SCN9A Q15858 2/20 0.43
MAPT P10636 3/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.38
THRB P10828 1/20 0.37
ENPP2 Q13822 1/20 0.37
EGLN2 Q96KS0 2/20 0.35
ADORA2A P29274 1/20 0.35
ADORA1 P30542 1/20 0.35
BCL6 P41182 1/20 0.35
ITGB2 P05107 1/20 0.34
ICAM1 P05362 1/20 0.34
ITGAL P20701 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15020690 1.00 ALDH1A1 (0.47) ALDH1A1HPGDGAASMN1; SMN2HSD17B10
SCHEMBL15020820 0.93 FPR2 (0.42) ALDH1A1HPGDGAASMN1; SMN2HSD17B10
SCHEMBL256991 0.93 FPR2 (0.42) ALDH1A1HPGDGAASMN1; SMN2HSD17B10
SCHEMBL15042225 0.92 BCL6 (0.41) ALDH1A1HPGDGAASMN1; SMN2HSD17B10
SCHEMBL15021475 0.92 FPR2 (0.41) ALDH1A1HPGDGAASMN1; SMN2HSD17B10
SCHEMBL15021474 0.92 FPR2 (0.41) ALDH1A1HPGDGAASMN1; SMN2HSD17B10
SCHEMBL15021002 0.92 ALDH1A1 (0.40) ALDH1A1HPGDGAASMN1; SMN2HSD17B10
SCHEMBL15020888 0.91 FPR2 (0.42) ALDH1A1HPGDGAASMN1; SMN2HSD17B10
SCHEMBL15020887 0.91 FPR2 (0.42) ALDH1A1HPGDGAASMN1; SMN2HSD17B10
SCHEMBL15020613 0.90 FPR2 (0.45) ALDH1A1HPGDGAAHSD17B10FPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 EP disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
WO-2012030170-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR (주)아모레퍼시픽 (KR) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 ALDH1A1 2139/4885HPGD 1531/4885GAA 3078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.